Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone

Takahiro Mimae, Naruto Taira, Shozo Ohsumi, Daisuke Takabatake, Seiki Takashima, Kenjirou Aogi, Shigemitsu Takashima, Rieko Nishimura

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. However, about 10-35% of the patients don't benefit from this treatment This study was designed to evaluate predictive values of biological markers in response of breast cancers treated with docetaxel alone as neoadjuvant chemotherapy. METHODS: 36 patients received the planned four courses of preoperative docetaxel (60-75 mg/m 2) every 3 weeks. We evaluated the relationship between the response rate to neoadjuvant chemotherapy and hormonal receptor, HER2 status or nuclear grades. RESULTS: Clinical response rate was 57.2%. Pathological complete response rate was 5.6%. Clinical response rate by each factors were as follows; 9 (50%) in ER-positive tumors, 10 (66.7%) in ER-negative (p=0.27), 7 (50%) in PgR-positive, 12 (63.3%) in PgR-negative (p=0.34), 5 (55.6%) in HER2-positive, 14 (58.3%) in HER2-negative (p=0.71), 4 (50%) in tumors of low nuclear grade and 13 (65%) in ones of high nuclear grade (p=0.38). CONCLUSION: The possibility that tumors with negative hormonal receptors or of high nuclear grade tend to respond to neoadjuvant chemotherapy with docetaxel alone more likely was suggested. It is thought breast cancers respond to neoadjuvant chemotherapy of docetaxel alone regardless of HER2 status.

Original languageEnglish
Pages (from-to)619-622
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume36
Issue number4
Publication statusPublished - Apr 2009
Externally publishedYes

Fingerprint

docetaxel
Breast Neoplasms
Drug Therapy
Neoplasms
Biomarkers

Keywords

  • Docetaxel
  • HER2
  • Hormonal receptor
  • Neoadjuvant chemotherapy
  • Nuclear grade

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone. / Mimae, Takahiro; Taira, Naruto; Ohsumi, Shozo; Takabatake, Daisuke; Takashima, Seiki; Aogi, Kenjirou; Takashima, Shigemitsu; Nishimura, Rieko.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 36, No. 4, 04.2009, p. 619-622.

Research output: Contribution to journalArticle

Mimae, Takahiro ; Taira, Naruto ; Ohsumi, Shozo ; Takabatake, Daisuke ; Takashima, Seiki ; Aogi, Kenjirou ; Takashima, Shigemitsu ; Nishimura, Rieko. / Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2009 ; Vol. 36, No. 4. pp. 619-622.
@article{4b663ffcc6ae44a292f9c1a8f2efbda3,
title = "Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone",
abstract = "BACKGROUND: Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. However, about 10-35{\%} of the patients don't benefit from this treatment This study was designed to evaluate predictive values of biological markers in response of breast cancers treated with docetaxel alone as neoadjuvant chemotherapy. METHODS: 36 patients received the planned four courses of preoperative docetaxel (60-75 mg/m 2) every 3 weeks. We evaluated the relationship between the response rate to neoadjuvant chemotherapy and hormonal receptor, HER2 status or nuclear grades. RESULTS: Clinical response rate was 57.2{\%}. Pathological complete response rate was 5.6{\%}. Clinical response rate by each factors were as follows; 9 (50{\%}) in ER-positive tumors, 10 (66.7{\%}) in ER-negative (p=0.27), 7 (50{\%}) in PgR-positive, 12 (63.3{\%}) in PgR-negative (p=0.34), 5 (55.6{\%}) in HER2-positive, 14 (58.3{\%}) in HER2-negative (p=0.71), 4 (50{\%}) in tumors of low nuclear grade and 13 (65{\%}) in ones of high nuclear grade (p=0.38). CONCLUSION: The possibility that tumors with negative hormonal receptors or of high nuclear grade tend to respond to neoadjuvant chemotherapy with docetaxel alone more likely was suggested. It is thought breast cancers respond to neoadjuvant chemotherapy of docetaxel alone regardless of HER2 status.",
keywords = "Docetaxel, HER2, Hormonal receptor, Neoadjuvant chemotherapy, Nuclear grade",
author = "Takahiro Mimae and Naruto Taira and Shozo Ohsumi and Daisuke Takabatake and Seiki Takashima and Kenjirou Aogi and Shigemitsu Takashima and Rieko Nishimura",
year = "2009",
month = "4",
language = "English",
volume = "36",
pages = "619--622",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "4",

}

TY - JOUR

T1 - Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone

AU - Mimae, Takahiro

AU - Taira, Naruto

AU - Ohsumi, Shozo

AU - Takabatake, Daisuke

AU - Takashima, Seiki

AU - Aogi, Kenjirou

AU - Takashima, Shigemitsu

AU - Nishimura, Rieko

PY - 2009/4

Y1 - 2009/4

N2 - BACKGROUND: Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. However, about 10-35% of the patients don't benefit from this treatment This study was designed to evaluate predictive values of biological markers in response of breast cancers treated with docetaxel alone as neoadjuvant chemotherapy. METHODS: 36 patients received the planned four courses of preoperative docetaxel (60-75 mg/m 2) every 3 weeks. We evaluated the relationship between the response rate to neoadjuvant chemotherapy and hormonal receptor, HER2 status or nuclear grades. RESULTS: Clinical response rate was 57.2%. Pathological complete response rate was 5.6%. Clinical response rate by each factors were as follows; 9 (50%) in ER-positive tumors, 10 (66.7%) in ER-negative (p=0.27), 7 (50%) in PgR-positive, 12 (63.3%) in PgR-negative (p=0.34), 5 (55.6%) in HER2-positive, 14 (58.3%) in HER2-negative (p=0.71), 4 (50%) in tumors of low nuclear grade and 13 (65%) in ones of high nuclear grade (p=0.38). CONCLUSION: The possibility that tumors with negative hormonal receptors or of high nuclear grade tend to respond to neoadjuvant chemotherapy with docetaxel alone more likely was suggested. It is thought breast cancers respond to neoadjuvant chemotherapy of docetaxel alone regardless of HER2 status.

AB - BACKGROUND: Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. However, about 10-35% of the patients don't benefit from this treatment This study was designed to evaluate predictive values of biological markers in response of breast cancers treated with docetaxel alone as neoadjuvant chemotherapy. METHODS: 36 patients received the planned four courses of preoperative docetaxel (60-75 mg/m 2) every 3 weeks. We evaluated the relationship between the response rate to neoadjuvant chemotherapy and hormonal receptor, HER2 status or nuclear grades. RESULTS: Clinical response rate was 57.2%. Pathological complete response rate was 5.6%. Clinical response rate by each factors were as follows; 9 (50%) in ER-positive tumors, 10 (66.7%) in ER-negative (p=0.27), 7 (50%) in PgR-positive, 12 (63.3%) in PgR-negative (p=0.34), 5 (55.6%) in HER2-positive, 14 (58.3%) in HER2-negative (p=0.71), 4 (50%) in tumors of low nuclear grade and 13 (65%) in ones of high nuclear grade (p=0.38). CONCLUSION: The possibility that tumors with negative hormonal receptors or of high nuclear grade tend to respond to neoadjuvant chemotherapy with docetaxel alone more likely was suggested. It is thought breast cancers respond to neoadjuvant chemotherapy of docetaxel alone regardless of HER2 status.

KW - Docetaxel

KW - HER2

KW - Hormonal receptor

KW - Neoadjuvant chemotherapy

KW - Nuclear grade

UR - http://www.scopus.com/inward/record.url?scp=79959838583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959838583&partnerID=8YFLogxK

M3 - Article

C2 - 19381035

AN - SCOPUS:79959838583

VL - 36

SP - 619

EP - 622

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 4

ER -